The European Medicines Agency (EMA) also requested an unplanned post-hoc analysis based on PD-L1 expression levels in tumor cells in the initial biopsy, with a benefit being observed in terms of DFS irrespective of PD-L1 expression but no impact on OS in the specific PD-L1-negative subgroup (PD-L1 <1%). The gene discussed is CD274; the disease is neoplasm.